“Cannvalate is our #1 shareholder and their CEO Sud is our CMO.”
There’s something really...unconventional about this. The vested interest play doesn’t sit too well with me (despite their fantastic oil sales). Regular posters know I’ve expressed this before. But those who are also in medtech/biotech/pharma would agree, it is a highly unusual situation.
Not trying to put a dampener on anything whatsoever, the optics are just somewhat dubious. It also positions Cannvalate extremely well for a hostile takeover if it comes to it, given Sud has a huge packet.
Honestly though, at this rate, this is literally my only concern. And even then, it’s a 1%er.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
